

Staphylococcal Biofilms: Challenges in the Discovery of Novel Anti-infective Agents

Domenico Schillaci*

Department STEMBIO, Università degli Studi di Palermo, Via Archirafi 32, 90123-Palermo, Italy

Staphylococci can induce a wide spectrum of infectious diseases that are associated with remarkable morbidity and mortality [1]. In fact, community and hospital-acquired methicillin resistant *Staphylococcus aureus* (MRSA) is a major health problem that has created a pressing need for novel therapeutic options [2]. Importantly, pathogenic staphylococci have not only an amazing ability to acquire resistance to antibiotics, but also to form biofilms, bacterial communities that grow on surfaces and are surrounded by a self-produced polymer matrix. This latter characteristic is likely the most important virulence factor of staphylococci in the development of the chronic form of infectious diseases in humans such as otitis media, osteomyelitis, endophthalmitis, urinary tract infections, acute septic arthritis, native valve endocarditis, burn or wound infections and cystic fibrosis associated infections [3-9].

Staphylococcal biofilms are particularly dangerous because they are more resistant to host immune defence systems and have a significantly increased tolerance to antibiotics [10]. The polymer matrix of a biofilm retards the rate of antibiotic penetration of antibiotics such that the expression of genes within the biofilm that mediate resistance can be induced [3]. This is compounded by the fact that bacterial cells growing in biofilm show increased horizontal gene transmission, which can facilitate the spread antibiotic resistance traits [11].

The recurrence of some staphylococcal infections in the hospital setting has been attributed to the existence of specialized persister cells [12]. In *S. aureus* biofilms, although these persister cells do not grow in the presence of an antibiotic, they also do not die. When the drug is removed, the persister cells will give rise to a normal bacterial colony. It has been observed that *S. aureus* in biofilms is 100–1000 times less susceptible to antibiotics than equivalent bacterial populations of single cells (planktonic) [13]. Although conventional antibiotics can be effective against planktonic cells, there are currently no therapies that effectively target staphylococcal biofilms.

Staphylococcal biofilms are also responsible for many biomaterial-associated infections (BAI). Together, the Gram-positive pathogens *S. aureus*, *S. epidermidis* and *Enterococcus faecalis* represent more than 50% of the species isolated from patients with medical device-associated infections [15]. *S. aureus* is often the cause of metal-biomaterial infections, while *Staphylococcus epidermidis* is seen more often in polymer associated infections [14].

The continual increase in the use of medical devices is associated with a significant risk of infectious complications, septic thrombophlebitis, endocarditis, metastatic infections, and sepsis [17,18]. Biofilm associated infections of indwelling medical devices are usually resolved after replacement of the device but involve a prolonged hospital stay and increased healthcare costs. In fact, the treatment of catheter-related bloodstream infections that arise during intensive care unit stays in four European countries (France, Germany, Italy, UK), has an estimated cost of € 163.9 million [16]. If one considers that an increasing number of elderly patients require indwelling medical devices like artificial knees and hips, it becomes clear that a new generation of anti-infective agents effective in the prevention or eradication of biofilms is needed [19].

There is undoubtedly an urgent need for novel treatments, strategies and anti-staphylococcal biofilm agents. In this field of preclinical research, three different approaches are followed: (i) screen based strategies, (ii) target-based strategies, and (iii) biofilm matrix targeting strategies. The screen based strategies involved screening novel compounds (synthetic or natural) for inhibition staphylococcal biofilms through direct effects on bacterial growth and viability. The hope is that these screens will identify agents that may serve as alternatives to conventional antibiotics. Target-based strategies, on the other hand, focus on identifying or developing compounds that specifically target pathways that are essential for staphylococcal biofilm formation. The biofilm matrix targeting strategies instead, are aimed at identifying enzymes that target staphylococcal biofilm matrix.

The first approach has led to the identification and characterization of a number of small synthetic organic molecules with anti-biofilm properties. For instance, a collection of 2-aminoimidazole/triazole were synthesized and screened for anti-biofilm activity and found to inhibit biofilm formation against *Acinetobacter baumannii*, *Staphylococcus aureus* and *Pseudomonas aeruginosa*. One such compound in this library demonstrated the most potent inhibitory effect against *S. aureus* biofilm formation that has been displayed by any 2-aminoimidazole derivative [20]. Furthermore, a recent study that looked at the anti-staphylococcal biofilm activity of pyrrolomycins C, D, F1, F2a, F2b, F3 naturally produced by *Actinosporangium vitaminophyllum* and *Streptomyces ssp.*, and of the synthesized related compounds I, II, III, found that some of the tested compounds were active at the lowest screening concentration of 0.045 µg/mL [22].

Slow-growing and non-dividing bacteria, such as the aforementioned persister cells, exhibit tolerance to many antibiotics and represent a reservoir for recurrent biofilm infections. Importantly, the novel porphyrin antibacterial agents, XF-70 and XF-73, which have rapid membrane-perturbing activity against *S. aureus*, were also active against growth-attenuated cells. These results support the hypothesis that membrane-active agents may be particularly effective in eradicating slow- or non-growing bacteria and suggest that XF-70 and XF-73 could be utilized to treat staphylococcal infections where the organisms have a slow rate of division, such as biofilm-associated infections of prosthetic devices [21].

***Corresponding author:** Domenico Schillaci, Department STEMBIO, Università degli Studi di Palermo, Via Archirafi 32, 90123-Palermo, Italy, Tel. +3909123891914; E-mail: dschill@unipa.it

Received March 30, 2011; Accepted June 17, 2011; Published June 21, 2011

Citation: Schillaci D (2011) Staphylococcal Biofilms: Challenges in the Discovery of Novel Anti-infective Agents. J Microbial Biochem Technol 3: iv-vi. doi:10.4172/1948-5948.10000e4

Copyright: © 2011 Schillaci D. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

In order to adequately assess the utility of any of these new compounds as antibiofilm agents, their toxicity against human cells must be evaluated and their selectivity indexes (ratio of cytotoxicity as IC_{50} to anti-biofilm concentration) determined. A selectivity index value >200 can be considered a good “safety margin” for a compound that will be used for potential therapeutic development as antimicrobial agent [23]. In fact, only those compounds that show good selectivity indexes can be considered promising inhibitors for developing novel agents against staphylococcal biofilms.

An interesting class of antimicrobial agents are the antimicrobial peptides (AMPs), which have different modes of action than those of conventional antibiotics. AMPs are small molecules with a broad antimicrobial spectrum. AMPs from different natural sources such as terrestrial or marine animals have been studied for their anti-staphylococcal biofilm activity. An example of a recently identified AMP is PSN-1, a novel 19 amino acid antimicrobial peptide of the phylloseptin family, isolated from the skin secretion of the waxy monkey frog, *Phyllomedusa sauvagei*. PSN-1 displayed broad-spectrum activity against a range of planktonic organisms with a high potency (MIC 5 μ M) against *Staphylococcus aureus*. In a specific bioassay *S. aureus* grown as a biofilm, the minimal biofilm eradication concentration (MBEC) was found to be of the same high potency (5 μ M) [24].

Some authors have focused on marine invertebrates as a source of new antimicrobial agents. AMPs from marine invertebrates display broad antimicrobial spectra, even against human pathogens. Indeed, many of these organisms are not fouled so they must possess an effective defense strategy to prevent bacterial adhesion. The 5kDa peptide fraction of the cytosol from coelomocytes (5-CC), the effector cells of *Paracentrotus lividus* (sea-urchin), showed antibiofilm properties against staphylococcal biofilms of reference strains *Staphylococcus epidermidis* DSM 3269 and *Staphylococcus aureus* ATCC 29213. The antimicrobial efficacy of 5-CC against biofilms of clinical strain *S. epidermidis* 1457 was also tested. At a sub-MIC concentration (31.7 mg/mL) of 5-CC the formation of young (6h old) and mature (24h old) staphylococcal biofilms was inhibited. The biological activity of 5-CC could be attributed to three novel antimicrobial peptides belonging to the sequence segment 9-41 of a beta-thymosin [25].

The second approach, aimed at developing target-based agents, represents a rational strategy for discovering staphylococcal biofilm inhibitors. Quorum-sensing (QS) is a complex regulatory mechanism in biofilm formation. It is a process that is dependent on the release of chemical signals called autoinducers. These autoinducers allow bacteria to assess the density of the local bacterial population and coordinate the expression of a wide array of genes and phenotypes including bacterial virulence and pathogenesis [26]. Among Gram-positive species, QS autoinducers are unmodified or post-transcriptionally modified peptides, cyclic thiolactone peptides (AIPs) [27]. It has been proposed that novel compounds with close sequence similarity to AIPs may function as antagonists and may provide an alternative way of treating *S. aureus* infections [26].

The *agr* (accessory gene regulation) system of *S. aureus* is a model for QS systems in Gram-positive bacteria. The *agr* QS system consists of a four-gene operon (*agrB*, *agrD*, *agrC*, *agrA*) that synthesizes and secretes AIPs. AIPs bind to and activate *agrC*, a membrane bound histidine sensor kinase (the major environmental sensory system in prokaryotic cells), which in turn phosphorylates and activates *agrA*, a transcription factor that regulates the production of the effector molecule RNAPIII. Interestingly, a mechanism that interferes with biofilm formation in *S. aureus* involves the heptapeptide RNAPIII-

inhibiting peptide (RIP). This heptapeptide inhibits biofilm formation of *S. aureus* in vivo [28], possibly by blocking the *agr* dependent QS system [29]. In fact bone cement containing RIP has been patented as a means to prevent the colonisation and the development of biofilm on bone cement implant [30].

It is important to note, however, that the *agr* system might not be RIP's primary target. In fact, it has also been reported that inhibition of the *agr* system increases biofilm formation [31]. RIP appears to have an effect on biofilm formation, and as such, its structure is an interesting subject for modelling studies aimed at the identification of other biofilm inhibitors. Through structure based virtual screening using RIP as a template, hamamelitannin, a RIP non peptide-analogue derived from the bark of *Hamamelis virginiana* (witch hazel), that prevents device-associated MRSA infections in a concentration dependent manner was identified [32]. This work represents a clever variation of the structure-based screening approach in which the molecule used for modelling studies was not the target of a desired inhibitor, but itself an inhibitor [33].

The third approach consists in targeting the extracellular polymeric substance (EPS) matrix of bacterial biofilms. EPS is a complex mixture of components that can consist of polysaccharides, proteins, nucleic acids and/or lipids [34]. Purified N-acetylglucosaminidase, dispersin B, produced by the Gram-negative periodontal pathogen *Actinobacillus actinomycetemcomitans*, can dissolve mature biofilms produced by *Staphylococcus epidermidis* as well as some other bacterial species [35] by degrading polysaccharide intercellular adhesin (PIA) [36]. PIA is involved in the majority of staphylococcal biofilm associated infections and thus could be considered an ideal target for anti-biofilm drugs [37]. One recent study reported the synthesis of new polymeric matrices that can bind dispersin B alone or in combination with an antibiotic molecule, cefamandole nafate (CEF). These functionalized polyurethanes were able to adsorb a significant amount of dispersin B, which was able to exert its hydrolytic activity against the exopolysaccharide matrix produced by staphylococcal strains. When microbial biofilms were exposed to both dispersin B and CEF, a synergistic action became evident. Thus these polymer-dispersin B-antibiotic systems may be promising, highly effective tools for preventing bacterial colonization of medical devices [17]. Finally, a gel preparation containing dispersin B in combination with the disinfectant Triclosan has been marketed for the treatment of wound and skin infection and for disinfection of medical devices [38]. The downfall of this system is that, unfortunately, dispersin B cannot be used for the treatment of systemic biofilm-mediated infections, due to the immunogenic properties of bacterial enzymes [33]. The failure of conventional antibiotic therapy against bacterial biofilms can be attributed to the different mode of growth of pathogens as biofilms as opposed to planktonic pathogens. A chemotherapeutic approach that combines conventional antibiotics and novel anti-biofilm agents could be a new strategy for the treatment of biofilm associated infections. Some of the recently discovered inhibitors mentioned in this article show antibiofilm activity and selective toxicity, which make them good candidates for potential therapeutic development as effective chemical countermeasures against staphylococcal biofilms.

References

1. Tang YW, Stratton CW (2010) *Staphylococcus aureus*: An old pathogen with new weapons. Clin Lab Med 30: 179-208.
2. Ohlsen K, Lorenz U (2007) Novel targets for antibiotics in *Staphylococcus aureus*. Future Microbiol 2: 655-666.
3. Hall-Stoodley L and Stoodley P (2009) Evolving concepts in biofilm infections. Cellular Microbiology 11: 1034-1043.

4. Brady RA, Leid JG, Calhoun JH, Costerton JW, and Shirtliff ME (2008) Osteomyelitis and the role of biofilm in chronic infection FEMS. Immunol Med Microbiol 52: 13-22.
5. Callegan MC, Gilmore MS, Gregory M, Ramadan RT, Wiskur BJ, et al. (2007). Bacterial endophthalmitis: therapeutic challenges and host-pathogen interactions. Prog Retin Eye Res 26: 189-203.
6. Ronald A (2002) The etiology of urinary tract infection: traditional and emerging pathogens. Am J Med 113: 14-19.
7. Shirtliff ME, Mader JT (2002) Acute septic arthritis. Clin Microbiol Rev 15: 527-544.
8. Donlan RM, Costerton JW (2002) Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 15: 167-193.
9. Davies, Jane C, Bilton, Diana (2009) Bugs, biofilms, and resistance in cystic fibrosis. Respir Care 54: 628-640.
10. Høib N, Bjørnsholt T, Givskov M, Molin S, and Ciofu O (2010) Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents 35: 322-332.
11. Molin S, Tolker-Nielsen T (2003) Gene transfer occurs with enhanced efficiency in biofilms and induces enhanced stabilisation of the biofilm structure. Curr Opin Biotechnol 14: 255-261.
12. Lewis K (2007) Persister cells, dormancy and infectious disease. Nat Rev Microbiol 5: 48-56.
13. Gilbert P, Allison DG, McBain AJ (2002) Biofilms in vitro and in vivo: do singular mechanisms imply cross resistance? J Appl Microbiol 92: 98S-110S.
14. Götz F (2002) *Staphylococcus* and biofilms. Molecular Microbiology 43: 1367-1378.
15. Donelli G, De Paoli P, Fadda G, Marone P, Nicoletti G, et al. (2001) A multicenter study on central venous catheter-associated infections in Italy. J Chemother 13: 251-262.
16. Tacconelli E, Smith G, Hieke K, Lafuma A, Bastide P (2009). Epidemiology, medical outcomes and costs of catheter-related bloodstream infection in intensive care units of four European countries: literature- and registry-based estimates. J Hosp Infect 72: 97-103.
17. Donelli G, Francolini I, Romoli D, Guaglianone E, Piozzi A, et al. (2007) Synergistic activity of dispersin B and cefamandole nafate in inhibition of staphylococcal biofilm growth on polyurethanes. Antimicrob Agents Chemother 51: 2733-2740.
18. Parsek, MR, Singh PK (2003) Bacterial biofilms: an emerging link to disease pathogenesis. Annu Rev Microbiol 57: 677-701.
19. Lynch AS, Abbanat D (2010) New antibiotic agents and approaches to treat biofilm-associated infections. Expert Opin Ther Pat 20: 1373-1387.
20. Rogers SA, Huigens RW, Melander C (2009) 2-Aminobenzimidazole that inhibits and disperses gram-positive biofilms through a zinc-dependent mechanism. J Am Chem Soc 131: 9868-9869.
21. Ooi N, Miller K, Randall C, Rhys-Williams W, Love W, et al. (2010) XF-70 and XF-73, novel antibacterial agents active against slow-growing and non-dividing cultures of *Staphylococcus aureus* including biofilms. J Antimicrob Chemother 65: 72-78.
22. Schillaci D, Petruso S, Raimondi MV, Cusimano MG, Cascioferro S, et al. (2010) Pyrrolomycins as potential anti-staphylococcal biofilms agents. Biofouling 26:433-438.
23. Suto MJ, Domagala JM, Roland JE, Mailloux GB, Cohen MA (1992) Fluoroquinolones: relationships between structural variation, mammalian cell cytotoxicity, and antimicrobial activity. J Med Chem 35: 4745-4750.
24. Zhang R, Zhou M, Wang L, McGrath S, Chen T, et al. (2010) Phylloseptin-1 (PSN-1) from *Phyllomedusa sauvagei* skin secretion: a novel broad-spectrum antimicrobial peptide with antibiofilm activity. Mol Immunol 47: 2030-2037.
25. Schillaci, Arizza V, Parrinella N, Di Stefano V, Fanara S, et al. (2010) Antimicrobial and antistaphylococcal biofilm activity from the sea urchin *Paracentrotus lividus*. J Appl Microbiol 108:17-24.
26. Njoroge J, Sperandio J (2009) Jamming bacterial communication: new approaches for the treatment of infectious diseases. EMBO Mol Med 1:201-210.
27. Novick RP, Geisinger E. (2008) Quorum sensing in *staphylococci*. Annu Rev Genet 42:541-564.
28. Giacometti A, Cirioni O, Gov Y, Ghiselli R, Del Prete MS, et al. (2003) RNA III inhibiting peptide inhibits in vivo biofilm formation by drug-resistant *Staphylococcus aureus*. Antimicrob Agents Chemother 47:1979-1983.
29. Balaban N, Gov Y, Giacometti A, Cirioni O, Ghiselli R et al. (2004) A chimeric peptide composed of a dermaseptin derivative and an RNA III-inhibiting peptide prevents graft-associated infections by antibiotic-resistant *Staphylococci*. Antimicrob Agents Chemother 48:2544-2550.
30. Balaban N and Braunstein J (2007) Bone cement composition and the like comprising an RNAIII-inhibiting peptide. US 2007/092572.
31. Vuong C, Gerke C, Somerville GA, Fischer ER, Otto M (2003) Quorum-sensing control of biofilm factors in *Staphylococcus epidermidis*. J Infect Dis 188: 706-718.
32. Kiran MD, Giacometti A, Cirioni O, Balaban N (2008) Suppression of biofilm related, device associated infections by staphylococcal quorum sensing inhibitors. Int J Artif Organs 31: 761-770.
33. Landini P, Antoniani D, Burgess JG, Nijland R (2010) Molecular mechanisms of compounds affecting bacterial biofilm formation and dispersal. Appl Microbiol Biotechnol. 86: 813-823.
34. Flemming HC, Wingender J (2010) The biofilm matrix. Nat Rev Microbiol 8: 623-633.
35. Kaplan JB, Ragunath C, Velliyagounder K, Fine DH, Ramasubbu N (2004). Enzymatic detachment of *Staphylococcus epidermidis* biofilms. Antimicrob. Agents Chemother. 48: 2633-2636.
36. Kropec A, Maira-Litran T, Jefferson KK, Grout M, Cramton SE, Götz F, Goldmann DA, Pier GB (2005) Poly-N-acetylglucosamine production in *Staphylococcus aureus* is essential for virulence in murine models of systemic infection. Infect Immun. 73: 6868-6876.
37. Otto M (2008) Staphylococcal Biofilms. Curr Top Microbiol Immunol. 322: 207-228.
38. Darouiche RO, Mansouri MD, Gawande PV, Madhyastha S (2009). Antimicrobial and antibiofilm efficacy of triclosan and dispersinB combination. J Antimicrob Chemother 64: 88-93.